A pivotal Phase III trial of GALE-401 in patients with essential thrombocythemia

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 15 Jan 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Dec 2017 According to a Sellas Life Sciences Group media release, SELLAS Life Science Group acquired Galena Biopharma, and subsequently Galena Biopharma changed its name to SELLAS Life Science Group.
11 Sep 2017 According to a Galena Biopharma and BioVascular media release, both Galena Biopharma and BioVascular are responsible for the further development of GALE-401 (Phase 3-ready asset) drug for essential thrombocythemia.
15 Mar 2017 According to a Galena Biopharma media release, after the meeting US FDA confirmed that the GALE-401 development program is appropriate for a NDA filing using the 505(b)(2) regulatory pathway in patients with essential thrombocythemia who are intolerant or resistant to hydroxyurea.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com